Last $37.02 USD
Change Today +0.14 / 0.38%
Volume 234.8K
WX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 4:15 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

wuxi pharmatech cayman-adr (WX) Snapshot

Open
$36.88
Previous Close
$36.88
Day High
$37.09
Day Low
$36.71
52 Week High
02/25/14 - $40.72
52 Week Low
08/30/13 - $23.80
Market Cap
2.6B
Average Volume 10 Days
443.1K
EPS TTM
$1.41
Shares Outstanding
71.5M
EX-Date
--
P/E TM
26.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for WUXI PHARMATECH CAYMAN-ADR (WX)

wuxi pharmatech cayman-adr (WX) Related Businessweek News

No Related Businessweek News Found

wuxi pharmatech cayman-adr (WX) Details

WuXi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics; and laboratory services, including testing services for biologics, medical devices, and combination products. The Manufacturing Services segment produces and manufactures advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and for commercial products, as well as produces biologics. The company sells its products directly to pharmaceutical, biotechnology, and medical device companies. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is based in Shanghai, China.

7,445 Employees
Last Reported Date: 04/15/14
Founded in 2000

wuxi pharmatech cayman-adr (WX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

wuxi pharmatech cayman-adr (WX) Key Developments

WuXi PharmaTech (Cayman) Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Third Quarter and Full Year of 2014

WuXi PharmaTech (Cayman) Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total net revenue of $163,354,000 compared to $142,327,000 a year ago. Operating income was $28,003,000 compared to $25,692,000 a year ago. Income before income taxes was $36,011,000 compared to $33,491,000 a year ago. Net income was $29,336,000 compared to $29,620,000 a year ago. Basic net earnings per ADS was $0.42 compared to $0.42 a year ago. Diluted net earnings per ADS was $0.41 compared to $0.41 a year ago. Non-GAAP operating income was $33,924,000 compared to $29,806,000 a year ago. Non-GAAP net income was $35,241,000 compared to $33,713,000 a year ago. Non-GAAP basic earnings per ADS was $0.50 compared to $0.48 a year ago. Non-GAAP diluted earnings per ADS was $0.49 compared to $0.46 a year ago. Second-quarter net income fell 1% year on year due to mark-to-market losses on foreign-exchange forward contracts of $2.5 million, and a higher effective tax rate. For the six months, the company reported total net revenue of $310,071,000 compared to $274,192,000 a year ago. Operating income was $51,414,000 compared to $48,691,000 a year ago. Income before income taxes was $57,700,000 compared to $60,923,000 a year ago. Net income was $47,158,000 compared to $51,332,000 a year ago. Basic net earnings per ADS was $0.66 compared to $0.73 a year ago. Diluted net earnings per ADS was $0.65 compared to $0.71 a year ago. Non-GAAP operating income was $61,797,000 compared to $56,503,000 a year ago. Non-GAAP net income was $57,508,000 compared to $59,094,000 a year ago. Non-GAAP basic earnings per ADS was $0.81 compared to $0.84 a year ago. Non-GAAP diluted earnings per ADS was $0.79 compared to $0.82 a year ago. The company provided earnings guidance for the third quarter and full year of 2014. For the full year, the company expects net revenues of $665 million to $670 million, compared to previous guidance of $660 million to $670 million. GAAP diluted earnings per ADS of $1.55 to $1.59, compared to previous guidance of $1.53 to $1.58. Non-GAAP diluted earnings per ADS of $1.82 to $1.86, compared to previous guidance of $1.80 to $1.85. Capital expenditures expected to be of $95 million to $100 million, compared to previous guidance of about $85 million. For the third quarter, the company expects total net revenues of $171 million to $173 million. GAAP diluted earnings per ADS expected to be of $0.40 to $0.42. Non-GAAP diluted earnings per ADS expected to be of $0.48 to $0.50.

WuXi PharmaTech (Cayman) Inc. Announces Appointment of Walter Teh-Ming Kwauk as Independent Director

WuXi PharmaTech (Cayman) Inc. announced the appointment of Walter Teh-Ming Kwauk as an independent director to the Board of Directors. Mr. Kwauk will serve on the Audit Committee. Mr. Kwauk is currently a senior consultant at Motorola Solutions (China) Co. Ltd. He serves as a director of Thunder Power Co. Ltd.; Sinosoft Technology Group Ltd., of which he serves as chairman of the audit committee; China Fordoo Holdings Ltd., of which he serves as chairman of the audit committee; and several private companies. He was formerly a director of Alibaba.com Ltd. Mr. Kwauk worked for KPMG from 1977 to 2002 and held a number of senior positions, including the general manager of KPMG's joint venture accounting firm in Beijing, the managing partner in KPMG's Shanghai office, and a partner in KPMG's Hong Kong office.

WuXi PharmaTech (Cayman) Inc. to Report Q2, 2014 Results on Aug 13, 2014

WuXi PharmaTech (Cayman) Inc. announced that they will report Q2, 2014 results at 5:00 PM, China Standard Time on Aug 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WX:US $37.02 USD +0.14

WX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hangzhou Tigermed Consulting Co Ltd CNY32.05 CNY +1.60
View Industry Companies
 

Industry Analysis

WX

Industry Average

Valuation WX Industry Range
Price/Earnings 24.4x
Price/Sales 4.2x
Price/Book 3.7x
Price/Cash Flow 24.2x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WUXI PHARMATECH CAYMAN-ADR, please visit www.wuxiapptec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.